• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Aug. 4

Ranbaxy Laboratories Ltd announced on Friday that it has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Risperidone oral solution (1 mg/mL).

Risperdal (risperidone) is indicated for the treatment of schizophrenia.

The total annual market sales for risperidone oral solution were at $66 million. "We are pleased to receive this tentative approval for Risperidone oral solution.

This product represents a future opportunity for Ranbaxy and will be launched following final approval from the USFDA," Mr Jim Meehan, Vice-President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc, said.

Ranbaxy Pharmaceuticals Inc is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. It is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Stempeutics set for first stem cell trials

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line